News blog
Akers Biosciences Inc
- BY: Andrew Hore |
- POSTED: 05/01/2009 |
Akers Biosciences Inc is selling the intellectual property to its Free Radical Enzymatic Device for $3m.
Oregon-based Pulse Health is also buying future non-invasive exhaled breath test technology developed by Akers. Akers will continue to manufacture assay tubes for the test in return for a fixed price for three years plus a royalty per tube. This contract could be extended. Pulse will pay for any additional R&D undertaken on the product by Akers.
Akers still owns the rights to other products including the technology. These include the BreathScan Alcohol Detector and the Breath Ketone Check.
Shares in Akers rose 1.25p to 11.5p each, valuing the company at £12.8m.
© 2024 Aim Micro. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
- Browse by issue
- All issues
- Popular tags
- All tags
- AIM Micro feeds
Keep up to date with articles published at AIMMicro.com. Subscribe to AIM Micro RSS Feeds
|